Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia  by Hatta, Kotaro et al.
Schizophrenia Research 158 (2014) 213–222
Contents lists available at ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schresAntipsychotic switching versus augmentation among early
non-responders to risperidone or olanzapine in
acute-phase schizophreniaKotaro Hatta a,o,⁎, Taro Otachi b, Kiyoshi Fujita c, Fumiyoshi Morikawa d, Shin Ito e, Hirofumi Tomiyama f,
Takayuki Abe g, Yasuhiko Sudo h, Hiroshi Takebayashi i, Toru Yamashita j, Shigemasa Katayama k, ReikoNakase l,
Yutaka Shirai m, Chie Usui a, Hiroyuki Nakamura n, Hiroto Ito o, Toyoaki Hirata g, Yutaka Sawa p,
for the JAST study group
a Department of Psychiatry, Juntendo University Nerima Hospital, Tokyo, Japan
b Department of Psychiatry, Gunma Psychiatric Medical Center, Isezaki, Japan
c Department of Psychiatry, The Okehazama Hospital, Toyoake, Japan
d Department of Psychiatry, Asahikawa Keisenkai Hospital, Asahikawa, Japan
e Department of Psychiatry, Kumpukai Yamada Hospital, Tokyo, Japan
f Department of Psychiatry, National Hospital Organization Hizen Psychiatric Center, Yoshinogari, Japan
g Department of Psychiatry, Chiba Psychiatric Medical Center, Chiba, Japan
h Department of Psychiatry, Tosa Hospital, Kochi, Japan
i Department of Psychiatry, Saitama Prefectural Psychiatric Hospital, Ina-machi, Japan
j Department of Psychiatry, Yamanashi Prefectural Kita Hospital, Nirasaki, Japan
k Department of Psychiatry, Seijin Hospital, Tokyo, Japan
l Department of Psychiatry, Mie Prefectural Mental Medical Center, Tsu, Japan
m Department of Psychiatry, Hyogo Prefecture Kofu Hospital, Kobe, Japan
n Department of Environmental and Preventive Medicine, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
o Department of Social Psychiatry, National Center of Neurology and Psychiatry, Kodaira, Japan
p Department of Psychiatry, Sawa Hospital, Osaka, Japan⁎ Corresponding author at:Departmentof Psychiatry, Junt
E-mail address: khatta@juntendo.ac.jp (K. Hatta).
http://dx.doi.org/10.1016/j.schres.2014.07.015
0920-9964/© 2014 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 20 February 2014
Received in revised form 8 June 2014
Accepted 12 July 2014
Available online 31 July 2014
Keywords:
Early response
Combination
Add-on
Polypharmacy
Emergency
Randomized clinical trial
Purpose: We examined whether augmentation with olanzapine would be superior to switching to olanzapine
among early non-responders (ENRs) to risperidone, and whether augmentation with risperidone would be
superior to switching to risperidone among ENRs to olanzapine.
We performed a rater-blinded, randomized clinical trial at psychiatric emergency sites. Eligible patients were
newly admitted patients with acute schizophrenia. ENRs to the initial antipsychotic (Clinical Global
Impressions-Improvement Scale: ≥4 at 2 weeks) were allocated to receive either augmentation with or
switching to the other antipsychotic (RIS + OLZ vs. RIS-OLZ; OLZ + RIS vs. OLZ-RIS).
Results: Sixty patients who completed 2 weeks of risperidone treatment were divided into 33 early responders
(RIS-ER) and 27 ENRs (RIS + OLZ, n = 14; RIS-OLZ, n = 13). Although time to treatment discontinuation for
any cause was signiﬁcantly shorter in RIS + OLZ group (54.1 days [95% conﬁdence interval, 41.3-67.0]) than in
RIS-ER group (68.7 [61.2-76.2]; P= 0.050), it was not signiﬁcantly shorter in RIS-OLZ group (58.5 [43.1-73.9])
than in RIS-ER group (P= 0.19). Sixty patients who completed 2 weeks of olanzapine treatment were divided
into 36 early responders (OLZ-ER) and 24 ENRs (OLZ + RIS, n = 11; OLZ-RIS, n = 13). Although time to treat-
ment discontinuation for any cause was signiﬁcantly shorter in OLZ-RIS group (56.1 days [40.7-71.5]) than in
OLZ-ER group (74.9 [68.5-81.3]; P = 0.008), it was not signiﬁcantly shorter in OLZ + RIS group (64.6 [49.6-
79.6]) than in OLZ-ER group (P= 0.20).
Conclusion: Despite the lack of pharmacokinetic investigation of dose adequacy in this study, it is possible that
switching to olanzapine among ENRs to risperidone might have a small advantage over augmentation with
olanzapine, while augmentation with risperidone might have a small advantage over switching to risperidone
among ENRs to olanzapine. Further research is required before itwould be appropriate tomodify routine practice
in the direction of these ﬁndings.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).endoUniversityNerimaHospital, Takanodai 3-1-10,Nerima-ku, Tokyo177-8521, Japan. Tel.:+81359233111; fax:+81359233217.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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therapy is clearly optimal when both effective and tolerated. When a
patient fails to respond to an adequate dose of an antipsychotic, howev-
er, the alternatives include switching, administering a dose higher than
the licensed dose, polypharmacy or clozapine. Clozapine is the only
option with established efﬁcacy, but is lessmanageable than other anti-
psychotics, with a relatively high frequency of clozapine-induced
agranulocytosis. Other options therefore need to be comprehensively
evaluated, especially in acute-phase practice.
Previous studies have identiﬁed early non-response as a robust pre-
dictor of subsequent non-response with continued treatment of the
same medication (Derks et al., 2010; Kinon et al., 2010; Hatta et al.,
2011; O’Gorman et al., 2011; Levine and Leucht, 2012). The ﬁrst
randomized, double-blind study of whether ‘switching’ early non-
responders (ENRs) to another antipsychotic represents a better strategy
than ‘staying’ was reported by Kinon et al. (2010). They showed that
switching to risperidone in ENRs to olanzapine at week 2 resulted in a
small but signiﬁcantly greater reduction in PANSS total score and in
depressive symptoms.
The supporting evidence is minimal on polypharmacy. It has been
reported that the addition of aripiprazole to risperidone or quetiapine
was not associated with improvement in psychiatric symptoms but
was generally safe and well tolerated in a multicenter, double-blind,
placebo-controlled study (Kane et al, 2009). We have presented the
ﬁrst randomized clinical trial of olanzapine augmentation of risperidone
in patients non-responsive to risperidone monotherapy in the acute
phase (Hatta et al., 2012). In the study, early response was deﬁned as
CGI-I≤3 following 2 weeks of treatment, and ENRswere then allocated
to receive either augmentation with olanzapine (RIS + OLZ group) or
increased risperidone dose (RIS + RIS group). Although time to
treatment discontinuation for any cause was signiﬁcantly shorter in
the RIS + RIS group than in early responders (ERs) to risperidone, no
signiﬁcant difference was evident between the RIS + OLZ group and
ERs to risperidone. These ﬁndings justify the inclusion of augmentation
arms in additional, larger studies comparing strategies for ENRs in the
treatment of acute-phase schizophrenia.
We therefore prospectively examined whether augmentation with
olanzapine would be superior to switching to olanzapine in acute
schizophrenia patients showing early non-response to risperidone,
and whether augmentation with risperidone would be superior to
switching to risperidone in acute schizophrenia patients showing
early non-response to olanzapine. The present study was performed
with emergency-based, newly admitted patients without support
from pharmaceutical companies, reﬂecting real-world practice.2. Methods
2.1. Setting and participants
Of the 63 psychiatric emergency wards authorized by Japanese
government, 13 (21%) participated in the present study. These wards
were located all over Japan, and were responsible for local emergency
cases. Most patients from these hospitals were behavioral emergencies
and about 60% were brought in by the police. All were involuntary ad-
missions as an immediate danger to themselves or others, according
to the1995 LawConcerningMental Health andWelfare for theMentally
Disabled. Details of the clinical setting are described elsewhere (Hatta
et al., 1998). In Japan, psychiatric emergency services have been
enlarged in not only metropolitan, but also local areas according to gov-
ernment policy for 18 years. The quality of sites and patients in the
present study was therefore homogenous. This activity was conducted
by the Japan Acute-phase Schizophrenia Trial (JAST) study group
(Hatta et al., 2009).During the study period, between May 1, 2012 and June 30, 2013, a
total of 2,906 patientswere admitted and assessed for eligibility. Eligible
patients were 18-64 years old, newly admitted as emergency cases, and
met criteria of the DSM-IV-TR for schizophrenia, schizophreniform
disorder, or schizoaffective disorder. Patients with obvious complica-
tions such as liver dysfunction, renal dysfunction, heart failure, respira-
tory failure, or diabetes mellitus were excluded, as were patients who
were pregnant or who wanted to become pregnant.
2.2. Study design
All study protocols were approved by the institutional review board
at each site, and written informed consent was obtained from patients
or their legally authorized representatives. Patients who refused oral
medication were initially treated with injections. After resolution of
agitation, the investigators informed patients orally and in writing
about the trial, and invited them to participate.
Patients were treated with ﬂexible-dose oral risperidone or
olanzapine for 2 weeks. The decision of the initial antiosychotic, i.e. ris-
peridone or olanzapine, depends on the preference of treating psychia-
trists. Then, patients were divided according to the CGI-I into: ERs, CGI-I
score≤3; and ENRs, CGI-I score≥4. ERs to risperidone (RIS-ER) contin-
ued with risperidone therapy, whereas ENRs to risperidone were
randomized using the sealed envelope method in a rater-blind manner
to either switch to olanzapine (RIS-OLZ) or add olanzapine (RIS+ OLZ)
for the next 10 weeks. Also, ERs to olanzapine (OLZ-ER) continuedwith
olanzapine therapy, whereas ENRs to olanzapine were randomized
using the sealed envelope method in a rater-blind manner to either
switch to risperidone (OLZ-RIS) or add risperidone (OLZ + RIS) for
the next 10 weeks. For randomization,we referred to a randomnumber
table, with sequentially numbered, opaque, sealed envelopes used to
conceal the allocation sequence.
The initial dose of risperidone and olanzapine were 3 mg/day and
10 mg/day, respectively. Doses were subsequently increased or
decreased at the discretion of the treating psychiatrist. Use of benzodi-
azepines was allowed and documented. Use of valproate as a mood
stabilizer was also allowed and documented. However, use of other
mood stabilizers and antidepressants was not permitted. Use of anti-
cholinergic drugs was also not allowed unless acute extrapyramidal
side effects appeared.
2.3. Procedures
Before starting the trial, site-coordinatorswere trained to assess out-
comes as raters. A training video was used to train raters in the assess-
ment of the Positive and Negative Syndrome Scale (PANSS) (Kay et al.,
1991). The primary outcome measure was ≥40% improvement in the
PANSS total score and all-cause discontinuation. Efﬁcacy outcomes
consisted of PANSS, CGI-I (1 - verymuch improved, 2 - much improved,
3 - minimally improved, 4 - no change, 5 - minimally worse, 6 - much
worse, 7 - very much worse) (Guy, 1976), and the Global Assessment
of Functioning (GAF) (Jones et al., 1995). Safety and tolerability out-
comes were determined based on vital signs, weight, laboratory data,
electrocardiography (ECG), and the Drug-induced Extrapyramidal
Symptom Scale (DIEPSS), which includes parkinsonism, akathisia,
dystonia, and dyskinesia (Inada, 1996). Data including PANSS, CGI,
GAF, vital signs, weight, laboratory data, serum prolactin levels, ECG,
and DIEPSS were collected at the time of admission and every 2 weeks
thereafter. Data were also collected at the time of discontinuation of
allocated intervention. Sexual side effectswere recordedwhen reported
by patients, and sedation was recorded when described by patients as
an aversive subjective experience or when observed. Raters, who did
not work on the wards involved in the study, were not involved with
treatment, and were blinded to drug assignments to ENRs. The tested
drugwas discontinuedwhen the treating psychiatrist judged the efﬁca-
cy of the drug to be insufﬁcient, when the treating psychiatrist judged
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non-adherence. Before the judgment of insufﬁcient efﬁcacy, the drug
dosage was increased to the maximum.
2.4. Statistical analysis
The analyses were performed intention-to-treat. Differences
between categorical variables in patient demographics and clinical
characteristics were calculated using Fisher’s exact test. Differences
between sequential variables were calculated using the unpaired t test
(with Welch correction if applicable). When values were not sampled
from Gaussian distributions, non-parametric test (Mann-Whitney
Test) was used. Mean improvement in the PANSS total score was calcu-
lated as 100*(baseline score – week x score)/(baseline score – 30)
(Leucht et al., 2009). Changes in scores of PANSS total, Positive scale,
Negative scale, and General psychopathology scale up to 12 weeks
were analyzed. In addition, Positive factor, Negative factor, Disorga-
nized/concrete factor, Excited factor, and Depressed factor based on
the 5-factor model of the PANSS (Wallwork et al., 2012) were analyzed.
Missing values of PANSS scores were handled using the method of last-
observation-carried-forward (LOCF). Kaplan-Meier curveswere used to
estimate the probability of treatment discontinuation at 12 weeks.
Statistical analyses were performed using SPSS version 20.0 J
software (SPSS, Tokyo, Japan). All statistical tests were two-tailed.
Values of P b 0.05 were regarded as statistically signiﬁcant.
Our previous randomized clinical trial (RCT) (Hatta et al., 2011)
showed that the rate of ≥40% improvement in PANSS total score as
subsequent response among ENRs to risperidone and switched to
olanzapine (RIS-OLZ) was 11%. Another our RCT (Hatta et al., 2012)
showed that the rate of≥40% improvement in PANSS total score as sub-
sequent response among ENRs to risperidone and added olanzapine
(RIS + OLZ) was 62%. We thus assumed that subsequent response
among the RIS-OLZ group and the RIS + OLZ group were 11% and
62%, respectively. The statistical power was set as power = 1-β =
80%, and sensitivity asα=5% to be able to detect differences in the ef-
fects. Power analysis consequently set the required number of patients
at 13 patients per group.
Although the former RCT (Hatta et al., 2011) showed that the rate of
≥40% improvement in PANSS total score as subsequent response
among ENRs to olanzapine and switched to risperidone (OLZ-RIS) was
38%, as of the time of preparing this study, no evidence have been
presented regarding subsequent response to augmentation of risperi-
done among ENRs to olanzapine (OLZ + RIS).
This study is registered in the UMIN Clinical Trials Registry (number:
UMIN000007145; http://www.umin.ac.jp/ctr).
3. Results
Fig. 1 shows the trial proﬁle. Among 156 patients enrolled, 74 pa-
tients started on risperidone treatment, and 82 patients started on
olanzapine treatment. The rate of study participation among eligible
patients was 17% (156/901). Table 1 shows the characteristics of the
patients started on risperidone vs. olanzapine. Among 156 patients
enrolled, 86 patients (55%) were women. As shown in Table 1, there
are more women whose doctors chose olanzapine initially for them.
3.1. Results of patients whose initial antipsychotic was risperidone
One patient withdrew consent, and 9 patients discontinued risperi-
done treatment due to a lack of efﬁcacy before the end of the ﬁrst
2 weeks. In addition, 4 patients discontinued risperidone treatment
due to other reasons such as detection of comorbid diabetes mellitus
after enrollment (n= 2), change in diagnosis to other than schizophre-
nia, schizophreniform disorder, or schizoaffective disorder (n= 1), and
non-compliance with the study protocol (n = 1). Data from thesepatients were not included in the ﬁnal analysis. Thus, 60 patients com-
pleted 2 weeks of treatment.
These patients were divided into the early response to risperidone
group (RIS-ER, n= 33, 55%), and the early non-response to risperidone
group (n = 27, 45%), according to the CGI-I score at 2 weeks, as men-
tioned in 2.2. Baseline characteristics of patients were much the same
between groups except a few items (Table 2). The mean initial dose of
risperidone in the early non-response to risperidone group was signiﬁ-
cantly higher than that in the RIS-ER group. Themean scores of Negative
scale andNegative factor at baseline in the early non-response to risper-
idone group were signiﬁcantly higher than those in the RIS-ER group,
respectively. The similar result was obtained in themean score of Disor-
ganized/concrete factor at baseline.
The median dose of risperidone at 2 weeks in the RIS-ER group was
3.0 mg/day. In contrast, the median dose of risperidone at 2 weeks in
early non-responders to risperidone was 10.0 mg/day, as risperi-
done doses were gradually increased from the initial dose (median
3 mg/day, Table 2) due to insufﬁcient antipsychotic effects on acute
symptoms such as excitement associated with positive symptoms.
Mean CGI-I scores at 2 weeks in the RIS-ER group and the early
non-response to risperidone group were 2.2 (standard deviation
(SD), 0.7) and 4.1 (SD, 0.5), respectively. Mean improvements in
the PANSS total score between baseline and at 2 weeks in the RIS-
ER group (CGI-I 1, n = 6; CGI-I 2, n = 15; CGI-I 3, n = 12) and the
early non-response to risperidone group (CGI-I 4, n = 23; CGI-I 5,
n = 3; CGI-I 6, n = 1) were 38.0% (SD, 18.3) and 11.2% (SD, 15.0),
respectively. The early non-responders to risperidonewere allocated
to switching to olanzapine (RIS-OLZ, n = 13) or allocated to aug-
menting with olanzapine (RIS + OLZ, n = 14). There were no signif-
icant differences in baseline characteristics between the RIS-OLZ
group and the RIS + OLZ group (Table 3).
Between 2-12 weeks, 12 patients in the RIS-ER group discontinued
risperidone due to a lack of efﬁcacy (n = 5), side effects (n = 6), and
non-adherence (n= 1). Details of the side effects were extrapyramidal
symptoms (n=3), hyperprolactinemia (n=1), fever (n=1), and liver
dysfunction (n = 1). Seven patients in the RIS-OLZ group discontinued
allocated treatment due to insufﬁcient efﬁcacy (n= 5) and side effects
(n = 2). Both cases of side effects were agitation. Nine patients in the
RIS + OLZ group discontinued allocated treatment due to insufﬁcient
efﬁcacy (n = 7) and side effects (n = 2). Details of the side effects
were extrapyramidal symptoms (n = 1) and a fracture due to a fall
(n = 1). The ﬁnal mean dose of risperidone in the RIS-ER group
was 5.0 mg/day (SD 2.8), which was consistent with the recom-
mended dose of 2 to less than 6 mg/day in international standards
(Li et al, 2009)
Beyond our expectation, the rate of ≥40% improvement in PANSS
total in the RIS + OLZ group was not signiﬁcantly higher than that in
the RIS-OLZ group (29% vs. 8%, P = 0.33) (Table 4). Kaplan-Meier
estimates of days to discontinuation (95% CI) were 68.7 (61.2-76.2)
for the RIS-ER group, 54.1 (41.3-67.0) for the RIS + OLZ group, and
58.5 (43.1-73.9) for the RIS-OLZ group, respectively (Fig. 2A). Compari-
sons by log-rank test showed that there was no signiﬁcant difference in
time to treatment discontinuation between the RIS + OLZ group and
the RIS-OLZ group (P = 0.72). However, although time to treatment
discontinuation for any cause was signiﬁcantly shorter in the RIS +
OLZ group than in the RIS-ER group (P= 0.050), it was not signiﬁcantly
shorter in the RIS-OLZ group than in the RIS-ER group (P= 0.19).
There were no signiﬁcant differences in safety and tolerability
outcomes between the RIS + OLZ group and the RIS-OLZ group, except
serum prolactin concentrations (P= 0.038, Table 4).
3.2. Results of patients whose initial antipsychotic was olanzapine
Eighteen patients discontinued olanzapine treatment due to a lack of
efﬁcacy (n=17) and nausea (n=1) before the end of the ﬁrst 2 weeks
(Fig. 1). There is no statistically signiﬁcant difference in the dropout
Assessed for eligibility (n=2906)
Excluded (n=2750)
Not meeting inclusion criteria (n=2005)
Refused to participate (n=745)
Other reasons (n=0)
Lost to follow-up (n=0)
Withdrew consent (n=0)
Discontinued RIS (n=12)
5 insufficient efficacy
6 side-effects
1 non-adherence
CGI-I > 4 (n=27, early
non-responders)
Randomization (n=27)
Allocated to switching to OLZ
(n=13)
13 received allocated intervention
0 did not receive allocated
intervention
Allocated to augmenting with OLZ
(n=14)
14 received allocated intervention
0 did not receive allocated
intervention
Lost to follow-up (n=0)
Withdrew consent (n=1)
Discontinued RIS (n=9)
9 insufficient efficacy
0 side-effects
0 non-adherence
Others b (n=4)
At 12 weeks
Lost to follow-up (n=0)
Withdrew consent (n=0)
Discontinued allocated
intervention (n=7)
5 insufficient efficacy
2 side-effects
0 non-adherence
Lost to follow-up (n=0)
Withdrew consent (n=0)
Discontinued allocated
intervention (n=9)
7 insufficient efficacy
2 side-effects
0 non-adherence
CGI-I < 3 (n=33, early
responders)
At 2 weeks
RIS start (n=74)
At the time of emergency admission
Analyzed (n=33)
Excluded from analysis (n=0)
Analyzed (n=13)
Excluded from analysis (n=0)
Analyzed (n=14)
Excluded from analysis (n=0)
156 patients enrolled
Non-randomization a
OLZ start (n=82)
Lost to follow-up (n=0)
Withdrew consent (n=0)
Discontinued OLZ (n=7)
3 insufficient efficacy
2 side-effects
2 non-adherence
CGI-I > 4 (n=24, early
non-responders)
Randomization (n=24)
Allocated to switching to RIS
(n=13)
12 received allocated intervention
1 did not receive allocated
intervention
Allocated to augmenting with RIS
(n=11)
11 received allocated intervention
0 did not receive allocated
intervention
Lost to follow-up (n=0)
Withdrew consent (n=0)
Discontinued olanzapine (n=18)
17 insufficient efficacy
1 side-effects
0 non-adherence
Others c (n=4)
Lost to follow-up (n=0)
Withdrew consent (n=0)
Discontinued allocated
intervention (n=7)
7 insufficient efficacy
0 side-effects
0 non-adherence
Lost to follow-up (n=0)
Withdrew consent (n=0)
Discontinued allocated
intervention (n=4)
4 insufficient efficacy
0 side-effects
0 non-adherence
CGI-I < 3 (n=36, early
responders)
Analyzed (n=36)
Excluded from analysis (n=0)
Analyzed (n=13)
Excluded from analysis (n=0)
Analyzed (n=11)
Excluded from analysis (n=0)
Fig. 1. Trial proﬁle. Between May 1, 2012 and June 30, 2013, newly admitted emergency patients meeting the DSM-IV-TR criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder were started on risperidone or olanzapine
treatment. At 2 weeks, patients were divided according to the CGI-I into early responders and early non-responders to the initial antipsychotic. Early responders continued with the initial antipsychotic therapy, whereas early non-responders were
randomized to either switch to the other antipsychotic or add the other antipsychotic for the next 10 weeks. RIS, risperidone, OLZ, olanzapine. a At the discretion of the treating psychiatrist. b Detection of comorbid diabetes mellitus after
enrollment (n = 2), change in diagnosis to other than schizophrenia, schizophreniform disorder, or schizoaffective disorder (n = 1), non-compliance with the study protocol (n = 1). c Change in diagnosis to other than schizophrenia,
schizophreniform disorder, or schizoaffective disorder (n = 3), non-compliance with the study protocol (n = 1).
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Table 1
Comparison of baseline characteristics of the patients started on risperidone vs.
olanzapine.
Patients started
on risperidone
(n = 74)
Patients started
on olanzapine
(n = 82)
P
Age 40.5 (11.6) 42.2 (10.2) 0.35
Women 34/74 (46%) 52/82 (63%) 0.036
Asian 74/74 (100%) 82/82 (100%) 1.00
Diagnosis
Schizophrenia/schizophreniform 68/74 (92%) 73/82 (89%) 0.60
Schizoaffective 6/74 (8%) 9/82 (11%)
Substance dependence 6/74 (8%) 1/82 (1%) 0.10
Smoking 16/74 (22%) 14/82 (17%) 0.54
Duration from onset (year) 9.1 (9.6) 12.7 (10.2) 0.026
Antipsychotic-naive 37/74 (50%) 30/82 (37%) 0.11
Initial dose (mg/day) 3.0 (0.9) 10.9 (3.8)
Haloperidol injection received
before enrollment
12/74 (16%) 12/82 (15%) 0.83
CGI-S 5.6 (0.8) 5.7 (0.8) 0.33
PANSS
Total 118.6 (22.8) 117.9 (20.9) 0.85
Positive scale 30.4 (7.0) 30.6 (6.3) 0.88
Negative scale 29.0 (8.5) 28.2 (8.3) 0.56
General psychopathology scale 59.2 (11.6) 59.1 (10.8) 0.96
5-factor model of the PANSS
Positive factor 17.5 (4.0) 17.6 (3.6) 0.95
Negative factor 24.0 (7.5) 23.1 (7.4) 0.44
Disorganized/concrete factor 13.4 (3.6) 13.2 (3.8) 0.73
Excited factor 16.1 (5.1) 15.8 (4.9) 0.69
Depressed factor 8.1 (2.9) 8.9 (3.7) 0.16
GAF 23.6 (7.5) 22.0 (8.7) 0.20
BMI (kg/m2) 21.9 (4.4) 22.5 (4.1) 0.43
Rate of early-responders 33/74 (45%) 36/82 (44%) 1.00
Data represent mean (SD) or n/N (%), unless otherwise indicated. ‘Haloperidol injection
received before enrolment’: the maximal duration until enrollment was 3 days. CGI-S,
Clinical Global Impression Severity rating scale; PANSS, Positive and Negative Syndrome
Scale; GAF, Global Assessment of Functioning; BMI, body mass index. Differences in age,
duration from onset, CGI-S, PANSS, GAF, and BMI were calculated using the unpaired t-
test. Differences in sex, and frequencies of substance dependence, antipsychotic-naïve,
and haloperidol injection received before enrolment were calculated using the Fisher’s
exact test.
Table 2
Comparison of baseline characteristics between early responders and early non-
responders to risperidone.
Early responders
to risperidone
(n = 33)
Early non-responders
to risperidone
(n = 27)
P
Age 40.6 (11.9) 40.1 (11.0) 0.88
Men 17/33 (52%) 18/27 (67%) 0.30
Diagnosis
Schizophrenia/schizophreniform 33/33 (100%) 24/27 (89%) 0.08
Schizoaffective 0/33 (0%) 3/27 (11%) 6
Substance dependence 3/33 (9%) 2/27 (7%) 1.00
Smoking 7/33 (21%) 6/27 (22%) 1.00
Duration from onset (year) 7.7 (9.4) 12.3 (10.4) 0.077
Antipsychotic-naive 18/33 (55%) 12/27 (44%) 0.60
Initial dose (mg/day, median)a 3.0 3.0 0.027
Haloperidol injection received
before enrollment
7/33 (21%) 3/27 (11%) 0.49
CGI-S 5.5 (0.9) 5.6 (0.7) 0.88
PANSS
Total 111.6 (22.1) 121.2 (21.1) 0.094
Positive scale 29.4 (7.3) 29.8 (5.8) 0.81
Negative scale 26.2 (8.1) 31.9 (7.4) 0.0064
General psychopathology scale 56.1 (11.0) 59.5 (11.4) 0.24
5-factor model of the PANSS
Positive factor 16.9 (4.3) 17.3 (3.6) 0.66
Negative factor 21.4 (7.0) 26.6 (6.8) 0.0051
Disorganized/concrete factor 12.1 (3.5) 14.2 (3.3) 0.018
Excited factor 15.3 (5.0) 15.4 (4.8) 0.94
Depressed factor 8.4 (2.9) 7.8 (2.7) 0.38
GAF 24.5 (6.9) 24.8 (8.1) 0.88
BMI (kg/m2) 21.3 (2.9) 22.7 (5.5) 0.25
Data represent mean (SD) or n/N (%), unless otherwise indicated. CGI-S, Clinical Global
Impression Severity rating scale; PANSS, Positive and Negative Syndrome Scale; GAF,
Global Assessment of Functioning; BMI, body mass index.
a As valueswere not sampled from Gaussian distributions, non-parametric test (Mann-
Whitney Test) was used.
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initiated on olanzapine and the patients initiated on risperidone (21%
vs. 12%, P= 0.20). In addition, 4 patients discontinued olanzapine treat-
ment due to other reasons such as change in diagnosis to other than
schizophrenia, schizophreniform disorder, or schizoaffective disorder
(n = 3) and non-compliance with the study protocol (n = 1). Data
from these patients were not included in the ﬁnal analysis. Thus, 60
patients completed 2 weeks of treatment.
These patients were divided into the early response to olanzapine
group (OLZ-ER, n= 36, 60%), and the early non-response to olanzapine
group (n = 24, 40%), according to the CGI-I score at 2 weeks, as men-
tioned in 2.2. Baseline characteristics of patients were much the same
between groups except one item (Table 5). The rate of women in the
early non-response to olanzapine group was signiﬁcantly higher than
that in the OLZ-ER group.
The median doses of olanzapine at 2 weeks in the OLZ-ER group
and early non-responders to olanzepine were 15.0 mg/day and
20.0 mg/day, respectively (P = 0.011). Mean CGI-I scores at 2 weeks
in the OLZ-ER group and the early non-response to olanzapine group
were 2.3 (SD, 0.8) and 4.2 (SD, 0.5), respectively. Mean improvements
in the PANSS total score between baseline and at 2 weeks in the OLZ-
ER group (CGI-I 1, n = 6; CGI-I 2, n = 12; CGI-I 3, n = 18) and the
early non-response to olanzapine group (CGI-I 4, n = 20; CGI-I 5, n =
3; CGI-I 6, n=1)were 42.1% (SD, 17.7) and 11.5% (SD, 13.5), respective-
ly. The early non-responders to olanzapine were allocated to switching
to risperidone (OLZ-RIS, n = 13) or allocated to augmenting with
risperidone (OLZ + RIS, n = 11). There were no signiﬁcant differencesin baseline characteristics between the OLZ-RIS group and the OLZ +
RIS group (Table 6).
Between 2-12 weeks, 7 patients in the OLZ-ER group discontinued
olanzapine due to a lack of efﬁcacy (n = 3), side effects (n = 2), and
non-adherence (n= 2). Details of the side effects were extrapyramidal
symptoms (n = 1) and hyperprolactinemia (n = 1). Seven patients in
the OLZ-RIS group discontinued allocated treatment due to insufﬁcient
efﬁcacy. Four patients in the OLZ + RIS group discontinued allocated
treatment due to insufﬁcient efﬁcacy. The ﬁnal dose of olanzapine in
the OLZ-ER group was 15.0 mg/day (median), which was the same as
the median dose at 2 weeks.
The rate of ≥40% improvement in PANSS total in the OLZ + RIS
group was not signiﬁcantly higher than that in the OLZ-RIS group
(50% vs. 25%, P = 0.38) (Table 7). Kaplan-Meier estimates of days to
discontinuation (95% CI) were 74.9 (68.5-81.3) for the OLZ-ER group,
64.6 (49.6-79.6) for the OLZ + RIS group, and 56.1 (40.7-71.5) for the
OLZ-RIS group, respectively (Fig. 2B). Comparisons by log-rank test
showed that there was no signiﬁcant difference in time to treatment
discontinuation between the RIS + OLZ group and the RIS-OLZ group
(P = 0.40). However, although time to treatment discontinuation
for any cause was signiﬁcantly shorter in the OLZ-RIS group than in
the OLZ-ER group (P = 0.008), it was not signiﬁcantly shorter in
the OLZ + RIS group than in the OLZ-ER group (P = 0.20).
There were no signiﬁcant differences in safety and tolerability out-
comes between the OLZ + RIS group and the OLZ-RIS group (Table 7).
4. Discussion
So far there is no randomized clinical trial comparing antipsychotic
augmentation and switching for the strategies of early non-response
Table 3
Comparison of baseline characteristics between early non-responders to risperidone
allocated to switching to olanzapine and those allocated to augmenting with olanzapine.
Switching to
olanzapine
(n = 13)
Augmenting with
olanzapine (n = 14)
P
Age 39.1 (12.6) 41.1 (9.7) 0.63
Men 10/13 (77%) 8/14 (57%) 0.42
Diagnosis
Schizophrenia/
schizophreniform
12/13 (92%) 12/14 (86%) 1.00
Schizoaffective 1/13 (8%) 2/14 (14%)
Substance dependence 1/13 (8%) 1/14 (7%) 1.00
Smoking 3/13 (23%) 3/14 (21%) 1.00
Duration from onset (year) 9.6 (10.6) 14.8 (10.1) 0.20
Antipsychotic-naive 8/13 (62%) 4/14 (29%) 0.13
Initial dose (mg/day) 3.3 (0.6) 3.3 (0.9) 0.94
Haloperidol injection
received before
enrollment
3/13 (23%) 0/14 (0%) 0.098
CGI-S 5.5 (0.7) 5.7 (0.8) 0.41
PANSS
Total 121.5 (18.8) 120.8 (23.7) 0.93
Positive scale 29.5 (5.9) 30.1 (5.9) 0.79
Negative scale 31.9 (7.3) 31.9 (7.8) 0.98
General psychopathology
scale
60.2 (10.1) 58.9 (12.7) 0.77
5-factor model of the
PANSS
Positive factor 16.8 (3.5) 17.9 (3.6) 0.44
Negative factor 26.6 (6.3) 26.6 (7.4) 0.99
Disorganized/concrete
factor
14.6 (2.4) 13.9 (4.0) 0.56
Excited factor 15.5 (4.0) 15.2 (5.5) 0.86
Depressed factor 8.0 (3.1) 7.6 (2.3) 0.68
GAF 23.8 (6.8) 25.8 (9.3) 0.53
BMI (kg/m2) 20.9 (3.1) 24.3 (6.7) 0.12
Data represent mean (SD) or n/N (%), unless otherwise indicated. CGI-S, Clinical Global
Impression Severity rating scale; PANSS, Positive and Negative Syndrome Scale; GAF,
Global Assessment of Functioning; BMI, body mass index.
Table 4
Comparison of outcomes between early non-responders to risperidone allocated to
switching to olanzapine and those allocated to augmenting with olanzapine.
Switching to
olanzapine
(n = 13)
Augmenting with
olanzapine
(n = 14)
P
Dose of risperidone at 2 weeks
(mg/day)
10.2 (2.5) 8.7 (3.6) 0.24
Max. dose of risperidone after
2 weeks (mg/day)
0 9.0 (4.0)
Max. dose of olanzapine (mg/day) 18.8 (8.2) 16.1 (5.6) 0.31
Adjunctive benzodiazepines 12/13 (92%) 12/14 (86%) 1.00
Adjunctive valproate 9/13 (69%) 6/14 (43%) 0.25
Anticholinergic drug 5/13 (38%) 6/14 (43%) 1.00
Discontinuation for any cause 7/13 (54%) 9/14 (64%) 0.70
Insufﬁcient efﬁcacy 5/13 (38%) 7/14 (50%) 0.70
Side-effects 2/13 (15%) 2/14 (14%) 1.00
Non-adherence 0/13 (0%) 0/14 (0%)
PANSS
Total -17.1 (13.6) -22.9 (19.2) 0.38
Positive scale -6.1 (4.5) -7.9 (6.9) 0.44
Negative scale -5.2 (7.1) -6.9 (7.0) 0.52
General psychopathology scale -7.5 (7.5) -10.2 (9.9) 0.43
5-factor model of the PANSS
Positive factor -3.3 (2.6) -4.5 (3.7) 0.35
Negative factor -3.6 (3.7) -4.5 (4.8) 0.60
Disorganized/concrete factor -1.8 (2.1) -2.2 (2.4) 0.68
Excited factor -3.8 (3.6) -3.6 (4.9) 0.91
Depressed factor -0.54 (1.8) -0.79 (1.9) 0.73
Percentage of improvement in
PANSS total
18.1 (15.2) 27.3 (24.7) 0.26
≥40% improvement in PANSS
total
1/13 (8%) 4/14 (29%) 0.33
CGI-I 4.6 (1.8) 3.8 (1.5) 0.20
GAF 34.3 (13.1) 40.9 (16.2) 0.26
Any serious adverse event 0/13 (0%) 0/14 (0%)
Extrapyramidal symptoms
(DIEPSS)
Any symptoms 9/13 (69%) 8/14 (57%) 0.69
Parkinsonism 7/13 (54%) 8/14 (57%) 1.00
Akathisia 2/13 (15%) 5/14 (36%) 0.38
Dystonia 2/13 (15%) 0/14 (0%) 0.22
Dyskinesia 1/13 (8%) 0/14 (0%) 0.48
Weight change from baseline (kg) -0.04 (2.83) -0.82 (3.95) 0.56
Fasting glucose change from
baseline (mg/dL)
7.8 (29.6) -2.4 (19.4) 0.30
Low density lipoprotein
cholesterol change from
baseline (mg/dL)
4.6 (28.9) -7.9 (18.0) 0.19
Triglycerides change from
baseline (mg/dL)
46.8 (120.7) -0.1 (84.8) 0.25
Prolactin (ng/mL) 51.8 (48.2) 113.7 (74.5) 0.038
Data represent mean (SD) or n/N (%), unless otherwise indicated. CGI-S, Clinical Global
Impression Severity rating scale; PANSS, Positive and Negative Syndrome Scale; GAF,
Global Assessment of Functioning; BMI.
218 K. Hatta et al. / Schizophrenia Research 158 (2014) 213–222to an initial antipsychotic in acute schizophrenia patients. In a prospec-
tive, observational, non-interventional study, Ascher-Svanum et al.
(2012) found that the patient’s worsening or lack of meaningful
improvement prompts clinicians to switch antipsychotic medications,
whereas when patients show some improvement, clinicians may be
more likely to try bolstering the improvements through augmentation.
In another non-interventional retrospective-prospective parallel arm
study from the Hungarian National Health Insurance Fund's database,
Katona et al. (2014) reported that switching to a new antipsychotic
after N60 days of monotherapy was superior to addition of a second
antipsychotic after N60 days of monotherapy for long-term sustained
treatment whereas the addition of a second antipsychotic had advan-
tage in mortality and psychiatric hospitalizations. From these ﬁndings,
Katona et al. concluded that combination treatments may be more
efﬁcacious during exacerbation of psychotic symptoms. However, the
study did not focus on early non-response to an antipsychotic as the
data were included after N60 days of monotherapy. In contrast,
the present study focusing on early non-response to an initial antipsy-
chotic may respond to real questions in acute-phase practice with ran-
domized design.
Interestingly, although time to treatment discontinuation was
signiﬁcantly shorter in the RIS + OLZ group than in the RIS-ER group,
it was not signiﬁcantly shorter in the RIS-OLZ group than in the RIS-ER
group. This ﬁnding indirectly suggests that switching to olanzapine is
superior to augmentation with olanzapine in early non-responders to
risperidone. There was no signiﬁcant difference in the rate of discontin-
uation due to side-effects between the RIS-OLZ group and the RIS+OLZ
group (15% vs. 14%, P = 1.00, Table 4). Therefore, it may be hard to
explain that the inferiority of the add-on of olanzapine to the switch
to olanzapine resulted from excessively high dose/level of risperidone.In contrast, although time to treatment discontinuation was signiﬁ-
cantly shorter in the OLZ-RIS group than in the OLZ-ER group, it was not
signiﬁcantly shorter in the OLZ + RIS group than in the OLZ-ER group.
This ﬁnding indirectly suggests that augmentation with risperidone is
superior to switching to risperidone in early non-responders to
olanzapine. In the Clinical Antipsychotic Trials of Intervention Effective-
ness (CATIE) study, patients who were on olanzapine at the time of
entry to the study and were assigned to other drugs during the initial
randomization didworse nomatter what theywere assigned to, includ-
ing risperidone (Essock et al., 2006). Although the characteristics of
early non-responders to olanzapine in the present study performed in
the emergency setting are considerably different from those of partici-
pants in the CATIE study ranging from partially remitted outpatients
to exaggerated inpatients (Stroup et al, 2003), the unsuccessful result
of switching to risperidone in early non-responders to olanzapine
might be partial replication of the ﬁnding of the CATIE study.
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Fig. 2. Time to treatment discontinuation for any cause.A)Patientswhose initial antipsychoticwas risperidone. Kaplan-Meier estimates of days to discontinuation (95% CI)were 68.7
(61.2-76.2) for theRIS-ER group, 54.1 (41.3-67.0) for theRIS+OLZ group, and 58.5 (43.1-73.9) for theRIS-OLZ group, respectively. Comparisons by log-rank test showed that therewas no
signiﬁcant difference in time to treatment discontinuation between the RIS + OLZ group and the RIS-OLZ group (P= 0.72). However, although time to treatment discontinuation was
signiﬁcantly shorter in the RIS + OLZ group than in the RIS-ER group (P= 0.050), it was not signiﬁcantly shorter in the RIS-OLZ group than in the RIS-ER group (P= 0.19). B) Patients
whose initial antipsychotic was olanzapine. Kaplan-Meier estimates of days to discontinuation (95% CI) were 74.9 (68.5-81.3) for the OLZ-ER group, 64.6 (49.6-79.6) for the OLZ + RIS
group, and 56.1 (40.7-71.5) for theOLZ-RIS group, respectively (Fig. 3B). Comparisons by log-rank test showed that therewasno signiﬁcant difference in time to treatment discontinuation
between the RIS + OLZ group and the RIS-OLZ group (P= 0.40). However, although time to treatment discontinuation was signiﬁcantly shorter in the OLZ-RIS group than in the OLZ-ER
group (P= 0.008), it was not signiﬁcantly shorter in the OLZ + RIS group than in the OLZ-ER group (P= 0.20).
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non-responders to risperidone, whereas there may be few responders
to risperidone alone among early non-responders to olanzapine. An
explanation may be that the difference in the clinical characteristics of
early responders and early non-responders between risperidone and
olanzapine. The mean scores of Negative scale/Negative factor and
Disorganized/concrete factor at baseline in early non-responders to
risperidone were signiﬁcantly higher than those in early responders toTable 5
Comparison of baseline characteristics between early responders and early non-
responders to olanzapine.
Early responders
to olanzapine
(n = 36)
Early
non-responders
to olanzapine
(n = 24)
P
Age 42.1 (11.0) 45.7 (9.7) 0.20
Men 18/36 (50%) 4/24 (17%) 0.013
Diagnosis
Schizophrenia/schizophreniform 31/36 (86%) 24/24 (100%) 0.0
Schizoaffective 5/36 (14%) 0/24 (0%) 77
Substance dependence 0/36 (0%) 1/24 (4%) 0.40
Smoking 11/36 (31%) 2/24 (8%) 0.056
Duration from onset (year) 11.3 (9.9) 15.1 (10.3) 0.16
Antipsychotic-naive 13/36 (36%) 10/24 (42%) 0.79
Initial dose (mg/day, median)a 10.0 10.0 0.46
Haloperidol injection received
before enrollment
6/36 (17%) 1/24 (4%) 0.23
CGI-S 5.8 (0.8) 5.6 (0.8) 0.41
PANSS
Total 114.6 (21.6) 114.9 (16.4) 0.96
Positive scale 29.1 (6.3) 30.4 (5.0) 0.40
Negative scale 26.9 (8.7) 27.6 (7.5) 0.77
General psychopathology scale 58.6 (11.6) 57.0 (8.8) 0.56
5-factor model of the PANSS
Positive factor 16.8 (3.7) 18.0 (3.1) 0.16
Negative factor 22.5 (8.0) 22.2 (6.4) 0.87
Disorganized/concrete factor 12.2 (4.0) 13.3 (2.9) 0.25
Excited factor 15.5 (5.1) 14.3 (3.6) 0.30
Depressed factor 9.3 (3.7) 8.1 (3.2) 0.18
GAF 21.7 (10.5) 24.3 (6.9) 0.26
BMI (kg/m2) 21.8 (3.7) 22.9 (5.0) 0.31
Data represent mean (SD) or n/N (%), unless otherwise indicated. CGI-S, Clinical Global
Impression Severity rating scale; PANSS, Positive and Negative Syndrome Scale; GAF,
Global Assessment of Functioning; BMI, body mass index.
a As valueswere not sampled fromGaussian distributions, non-parametric test (Mann-
Whitney Test) was used.risperidone, whereas such differences were not found between early
non-responders and early responders to olanzapine. Difference in phar-
macodynamics between risperidonewith high afﬁnity for 5-HT2 and D2
receptors and olanzapine as a multi-acting receptor targeted antipsy-
chotic might be associated with the present ﬁndings.
The impact of pharmacokinetics on adequacy of response, side
effects, and dropouts is also discussed. Although we did not measure
plasma levels of antipsychotics in the present study, we can speculate
that plasma olanzapine levels 2 weeks after olanzapine started may
have reached a therapeutic range even in early non-responders to
olanzapine from our recent study. We reported on serum olanzapine
concentrations for acute schizophrenia patients who required above
conventional doses in almost the same clinical setting as the present
study (Hatta et al, 2013). A total of 42 patients were randomly assigned
to receive risperidone (initial dose 3 mg/day) and olanzapine (initial
dose 10 mg/day), with follow-up at 8 weeks. Serum olanzapine
concentrations at the time of oral 20 mg/day could be obtained from 5
out of 7 patients who subsequently required high-dose olanzapine. All
values were more than 30 ng/mL after 11-16 hours from dosing
to sample collection, which proved sufﬁcient with respect to a
therapeutic level of 20 ng/mL (Mauri et al, 2007; Bishara et al, 2013).
Taking the ﬁnding into account, early non-response to olanzapine in
the present study might not be explained by the bioavailability of
olanzapine.
Both gender and smoking status affect olanzapine metabolism
signiﬁcantly. It has been reported that smokers cleared olanzapine
55% faster than non/past smokers, and that men cleared olanzapine
38% faster than women (Bigos et al, 2008). Also, it has been reported
that female nonsmokers had higher plasma olanzapine concentrations
for a given dose than male smokers (Patel et al, 2011). Surprisingly,
the rate of women was signiﬁcantly higher in early non-responders to
olanzapine than that in early responders, and the rate of smokers was
signiﬁcantly lower in early non-responders to olanzapine than that in
early responders. One explanation for these discrepancies is that the
primary cause of early non-response to olanzapine may not necessarily
be associated with pharmacokinetics and bioavailability, as mentioned
above (Hatta et al, 2013).
Also, as risperidone has active metabolites in contrast to olanzapine
(Mauri et al, 2007), early non-response to risperidone in the present
study might not be explained by the bioavailability of risperidone
even in patients without the ethnopsychopharmacology variable of "in-
termediate" metabolism alleles at P450 2D6 in a high percentage of
Table 6
Comparison of baseline characteristics between early non-responders to olanzapine
allocated to switching to risperidone and those allocated to augmenting with risperidone.
Switching to
risperidone (n = 13)
Augmenting
with risperidone
(n = 11)
P
Age 47.4 (9.4) 46.9 (8.1) 0.89
Men 2/12 (17%) 1/10 (10%) 1.00
Diagnosis
Schizophrenia/
schizophreniform
12/12 (100%) 10/10 (100%)
Schizoaffective 0/12 (0%) 0/10 (0%)
Substance dependence 12/12 (100%) 10/10 (100%)
Smoking 1/12 (8%) 2/10 (80%) 0.57
Duration from onset (year) 17.0 (11.0) 15.7 (8.6) 0.76
Antipsychotic-naive 4/12 (33%) 5/10 (50%) 0.67
Initial dose (mg/day) 10.0 (2.1) 11.0 (3.2) 0.39
Haloperidol injection received
before enrollment
1/12 (8%) 0/10 (0%) 1.00
CGI-S 5.7 (0.9) 5.3 (0.7) 0.24
PANSS
Total 118.2 (13.3) 112.8 (19.7) 0.46
Positive scale 30.3 (6.0) 30.6 (4.3) 0.91
Negative scale 28.4 (7.4) 27.1 (8.1) 0.70
General psychopathology
scale
59.4 (5.0) 55.1 (11.7) 0.26
5-factor model of the PANSS
Positive factor 17.7 (3.3) 18.9 (3.1) 0.38
Negative factor 23.2 (6.2) 21.7 (6.9) 0.60
Disorganized/concrete factor 13.7 (2.8) 13.4 (3.1) 0.84
Excited factor 15.0 (3.7) 12.8 (3.3) 0.16
Depressed factor 8.3 (4.1) 7.3 (1.9) 0.47
GAF 22.6 (7.1) 27.4 (5.0) 0.094
BMI (kg/m2) 22.4 (5.2) 23.9 (5.3) 0.55
Data represent mean (SD) or n/N (%), unless otherwise indicated. CGI-S, Clinical Global
Impression Severity rating scale; PANSS, Positive and Negative Syndrome Scale; GAF,
Global Assessment of Functioning; BMI, body mass index.
Table 7
Comparison of outcomes between early non-responders to olanzapine allocated to
switching to risperidone and those allocated to augmenting with risperidone.
Switching to
risperidone
(n = 13)
Augmenting with
risperidone
(n = 11)
P
Dose of olanzapine at 2 weeks
(mg/day)
17.9 (4.0) 19.0 (3.2) 0.58
Max. dose of olanzapine after
2 weeks (mg/day)
0 17.5 (5.4)
Max. dose of risperidone (mg/day) 8.2 (3.3) 8.1 (3.9) 0.97
Adjunctive benzodiazepines 9/12 (75%) 9/10 (90%) 0.59
Adjunctive valproate 8/12 (67%) 7/10 (70%) 1.00
Anticholinergic drug 4/12 (33%) 4/10 (40%) 1.00
Discontinuation for any cause 7/12 (58%) 4/10 (40%) 0.67
Insufﬁcient efﬁcacy 7/12 (58%) 4/10 (40%) 0.67
Side-effects 0/12 (0%) 0/10 (0%)
Non-adherence 0/12 (0%) 0/10 (0%)
PANSS
Total -18.2 (23.9) -36.1 (30.2) 0.14
Positive scale -6.9 (7.9) -11.7 (9.4) 0.21
Negative scale -15.5 (14.2) -15.6 (8.9) 0.98
General psychopathology scale -9.8 (13.3) -17.5 (13.4) 0.20
5-factor model of the PANSS
Positive factor -3.6 (4.2) -7.0 (5.3) 0.11
Negative factor -1.0 (2.8) -5.2 (6.6) 0.088
Disorganized/concrete factor -1.4 (4.0) -4.2 (3.6) 0.11
Excited factor -3.2 (4.4) -4.8 (4.6) 0.41
Depressed factor -1.8 (2.8) -1.6 (2.5) 0.84
Percentage of improvement in
PANSS total
21.7 (30.9) 39.6 (35.0) 0.22
≥40% improvement in PANSS
total
3/12 (25%) 5/10 (50%) 0.38
CGI-I 3.8 (1.5) 3.5 (1.7) 0.72
GAF 36.8 (16.2) 50.8 (17.4) 0.064
Any serious adverse event 0/12 (0%) 0/10 (0%)
Extrapyramidal symptoms
(DIEPSS)
Any symptoms 10/12 (83%) 9/10 (90%) 1.00
Parkinsonism 8/12 (67%) 9/10 (90%) 0.32
Akathisia 5/12 (42%) 5/10 (50%) 1.00
Dystonia 1/12 (8%) 0/10 (0%) 1.00
Dyskinesia 1/12 (8%) 0/10 (0%) 1.00
Weight change from
baseline (kg)
0.92 (4.2) 0.33 (3.1) 0.72
Fasting glucose change from
baseline (mg/dL)
-8.8 (23.3) -20.9 (36.5) 0.35
Low density lipoprotein
cholesterol change from
baseline (mg/dL)
-24.8 (31.2) -17.9 (49.2) 0.69
Triglycerides change from
baseline (mg/dL)
19.3 (56.3) 3.8 (108.0) 0.69
Prolactin (ng/mL) a 144.8 (96.0) 127.3 (61.5) 0.63
Data represent mean (SD) or n/N (%), unless otherwise indicated. CGI-S, Clinical Global
Impression Severity rating scale; PANSS, Positive and Negative Syndrome Scale; GAF,
Global Assessment of Functioning; BMI, a only female data.
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ma levels.
Thus, we suppose that plasma levels 2 weeks after risperidone or
olanzapine started may have been sufﬁcient in most early non-
responders. As there seems to be no interaction between risperidone
and olanzapine, each plasma level of risperidone and olanzapine at
endpoint after the augmentation may also have been sufﬁcient. There-
fore, a large number of dropouts due to side-effects caused by excessive
inhibition of dopaminergic neurotransmission were expected at end-
point after the augmentation. However, the numbers of such cases in
the RIS + OLZ group and the OLZ + RIS group were 2 (14%) and 0
(0%), respectively. In contrast, the numbers of early non-responders
showing ≥40% improvement in PANSS total in the RIS + OLZ group
and the OLZ + RIS group were 4 (29%) and 5 (50%), respectively.
These ﬁndings suggest that the bioavailability of risperidone and
olanzapine does not necessarily explain clinical response in some cases.
The rates of extrapyramidal symptoms were high in any of early
non-responder groups compared with the RIS-ER group (42%) or the
OLZ-ER group (19%). This seems that early non-responders may have
received excessive doses that are suboptimal for getting good overall
outcome, especially with risperidone, on the surface. Indeed, our doses
of 8-10 mg of risperidone in early non-responder groups at 2 weeks
are high by international standards. However, the initial dose of risper-
idone in early non-responders was 3 mg/day as well as that in the RIS-
ER group (Table 2). The median dose of risperidone at 2 weeks in the
RIS-ER group was still 3.0 mg/day, suggesting that clinicians tried to
keep minimum dose as long as antipsychotic effects were apparent in
the dose. In contrast, the median dose of risperidone at 2 weeks in
early non-responders to risperidone was 10.0 mg/day, as risperidone
doses were gradually increased from the initial dose due to insufﬁcient
antipsychotic effects. In this connection, the ﬁnal mean dose ofrisperidone in the RIS-ER group was 5.0 mg/day (SD 2.8), which was
consistent with the recommended dose of 2 to less than 6 mg/day in in-
ternational standards (Li et al, 2009). Thus, the high dose of risperidone
in early non-responders resulted from insufﬁcient effects on acute
symptoms such as excitement associated with positive symptoms in
the ordinary dose.
It may depend in part on pharmacokinetic variables based on the
patient's metabolic phenotype and phenocopies due to other drugs on
board. In future studies, it is needed to assess these variables and utilize
them in decision-making. Also, it will be required to have a control
group that stays on the same medication but has it optimized with
respect to bioavailability, using a combination of the blood level and
extrapyramidal symptoms as a gross measure of D2 receptor occupancy
to determine if the dose should be increased or decreased.
One strength of this study was that all participants were psychiatric
emergency cases requiring admission, mirroring real clinical practice.
221K. Hatta et al. / Schizophrenia Research 158 (2014) 213–222The absence of support from pharmaceutical companies was also a key
characteristic of this study. One limitation was that the sample size was
relatively small. Second, the study used a single-blind design. Obtaining
informed consent for a double-blinded study of emergency situations
may be extremely difﬁcult, and the rate of participation in a double-
blinded study among eligible patients could well be much lower than
that in a single-blinded study. As excessively low participation rates
cannot reﬂect real practice, this issue is of particular concern for re-
search into emergency situations. Third, there are more women
whose doctors chose olanzapine initially for them. One reason that
doctors tended to avoid risperidone in women may have been the pre-
disposition of risperidone to amenorrhea (Leucht et al, 2013). This
gender difference is a limitation of this study. Fourth, the rates of
adjunctive valproate and benzodiazepines were high. Although there
were no signiﬁcant differences in these rates between the RIS-OLZ
group and the RIS + OLZ group, and between the OLZ-RIS group and
the OLZ +RIS group, these adjunctive use may be as a factor obscuring
and confounding any conclusions about what effect the dependent var-
iables had on the results. Fifth, sexual side effects were recorded only
when spontaneously reported by patients. In the three groups on risper-
idone, the prolactin levels were very high - well into the 100 s on
average. There must have been a lot of sexual side effects, and this is a
weakness of this study.
The present randomized study suggests that switching to olanzapine
among early non-responders to risperidone might have a small advan-
tage over augmentation with olanzapine, while augmentation with
risperidonemight have a small advantage over switching to risperidone
among early non-responders to olanzapine. As 29-50% of early non-
responders allocated to augmentation showed ≥40% improvement in
PANSS total at endpoint, adding a second antipsychotic might be
allowed in acute-phase practice. However, there are a great many
confounding variables that could explain these results and there is
insufﬁcient justiﬁcation at this time for application of these ﬁnding to
routine clinical practice. We should be wary of polypharmacy, as multi-
ple agents are too often prescribed by clinicians when not warranted.
More studies performed in acute-phase practice with minimal bias are
required to assist clinicians in making rational treatment decisions.
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